KZR - Kezar Life Sciences, Inc.
| Previous Close | 24.88 |
| Open | 24.60 |
| Bid | 20.71 x 800 |
| Ask | 26.50 x 800 |
| Day's Range | 23.61 - 26.25 |
| 52 Week Range | 14.77 - 26.86 |
| Volume | 87,719 |
| Avg. Volume | 61,339 |
| Market Cap | 494.902M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
- GlobeNewswire•9 days ago
Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire•10 days ago
Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule.
- GlobeNewswire•3 months ago
Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018-- Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity ...
- PR Newswire•4 months ago
Former Pappas Portfolio Company CEO Retracts Anonymous Allegations
RESEARCH TRIANGLE PARK, N.C., July 17, 2018 /PRNewswire/ -- Pappas Capital announced today that Kenneth Ian Moch has retracted allegations of financial malfeasance that he made, anonymously, against two of the firm's senior executives. In the retraction letter, Mr. Moch acknowledged that "the statements that I made in the emails were false and it was wrong for me to send them." He also retracted all other disparaging statements that he made about Pappas Capital over the course of litigation that extended over more than two years. During a seven-month period beginning in October 2014, Mr. Moch sent a series of anonymous emails to several of the firm's largest investors and to the news media.
- PR Newswire•5 months ago
Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 /PRNewswire/ -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics ...
- PR Newswire•5 months ago
Kezar Life Sciences Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Kezar, before deducting underwriting discounts, commissions and offering expenses, is expected to be approximately $75 million. All of the common stock is being offered by Kezar.
- InvestorPlace•5 months ago
8 Biotech Stocks With IPOs This Week
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.
